245 related articles for article (PubMed ID: 38250075)
1. Expert consensus on the use of systemic glucocorticoids for managing eosinophil-related diseases.
Del Pozo V; Bobolea I; Rial MJ; Espigol-Frigolé G; Solans Laqué R; Hernández-Rivas JM; Mora E; Crespo-Lessmann A; Izquierdo Alonso JL; Domínguez Sosa MS; Maza-Solano J; Atienza-Mateo B; Bañas-Conejero D; Moure AL; Rúa-Figueroa Í
Front Immunol; 2023; 14():1310211. PubMed ID: 38250075
[TBL] [Abstract][Full Text] [Related]
2. Neutrophil infiltrates and eosinophil aggregates in chronic rhinosinusitis with nasal polyps and EGPA.
Contro G; Brescia G; Alessandrini L; Barion U; Padoan R; Frigo AC; Schiavon F; Marioni G
Clin Rheumatol; 2021 May; 40(5):1949-1957. PubMed ID: 33094393
[TBL] [Abstract][Full Text] [Related]
3. Eosinophilic respiratory disorders and the impact of biologics.
Bernstein JS; Wechsler ME
Curr Opin Pulm Med; 2023 May; 29(3):202-208. PubMed ID: 36866734
[TBL] [Abstract][Full Text] [Related]
4. Effect of Dupilumab on Blood Eosinophil Counts in Patients With Asthma, Chronic Rhinosinusitis With Nasal Polyps, Atopic Dermatitis, or Eosinophilic Esophagitis.
Wechsler ME; Klion AD; Paggiaro P; Nair P; Staumont-Salle D; Radwan A; Johnson RR; Kapoor U; Khokhar FA; Daizadeh N; Chen Z; Laws E; Ortiz B; Jacob-Nara JA; Mannent LP; Rowe PJ; Deniz Y
J Allergy Clin Immunol Pract; 2022 Oct; 10(10):2695-2709. PubMed ID: 35636689
[TBL] [Abstract][Full Text] [Related]
5. Eosinophilic granulomatosis with polyangitis: A new target for biologicals.
Bayrak Durmaz MS; Çelebi Sözener Z; Bavbek S
Tuberk Toraks; 2022 Mar; 70(1):93-101. PubMed ID: 35362309
[TBL] [Abstract][Full Text] [Related]
6. Eosinophilic granulomatosis with polyangiitis (Churg-Strauss) (EGPA) Consensus Task Force recommendations for evaluation and management.
Groh M; Pagnoux C; Baldini C; Bel E; Bottero P; Cottin V; Dalhoff K; Dunogué B; Gross W; Holle J; Humbert M; Jayne D; Jennette JC; Lazor R; Mahr A; Merkel PA; Mouthon L; Sinico RA; Specks U; Vaglio A; Wechsler ME; Cordier JF; Guillevin L
Eur J Intern Med; 2015 Sep; 26(7):545-53. PubMed ID: 25971154
[TBL] [Abstract][Full Text] [Related]
7. HES and EGPA: Two Sides of the Same Coin.
Khoury P; Akuthota P; Kwon N; Steinfeld J; Roufosse F
Mayo Clin Proc; 2023 Jul; 98(7):1054-1070. PubMed ID: 37419574
[TBL] [Abstract][Full Text] [Related]
8. Eosinophils and eosinophilic immune dysfunction in health and disease.
Jackson DJ; Akuthota P; Roufosse F
Eur Respir Rev; 2022 Mar; 31(163):. PubMed ID: 35082127
[TBL] [Abstract][Full Text] [Related]
9. Effectiveness and safety of anti-IL-5/Rα biologics in eosinophilic granulomatosis with polyangiitis: a two-year multicenter observational study.
Nolasco S; Portacci A; Campisi R; Buonamico E; Pelaia C; Benfante A; Triggiani M; Spadaro G; Caiaffa MF; Scioscia G; Detoraki A; Valenti G; Papia F; Tomasello A; Crimi N; Scichilone N; Pelaia G; Carpagnano GE; Crimi C
Front Immunol; 2023; 14():1204444. PubMed ID: 37457743
[TBL] [Abstract][Full Text] [Related]
10. Current and emerging biologic therapies targeting eosinophilic disorders.
Pitlick MM; Li JT; Pongdee T
World Allergy Organ J; 2022 Aug; 15(8):100676. PubMed ID: 35983569
[TBL] [Abstract][Full Text] [Related]
11. Rapid effect of benralizumab in exacerbation of severe eosinophilic asthma associated with eosinophilic granulomatosis with polyangiitis.
Martínez-Rivera C; Garcia-Olivé I; Urrutia-Royo B; Basagaña-Torrento M; Rosell A; Abad J
BMC Pulm Med; 2021 Jan; 21(1):35. PubMed ID: 33478439
[TBL] [Abstract][Full Text] [Related]
12. From DREAM to REALITI-A and beyond: Mepolizumab for the treatment of eosinophil-driven diseases.
Pavord ID; Bel EH; Bourdin A; Chan R; Han JK; Keene ON; Liu MC; Martin N; Papi A; Roufosse F; Steinfeld J; Wechsler ME; Yancey SW
Allergy; 2022 Mar; 77(3):778-797. PubMed ID: 34402066
[TBL] [Abstract][Full Text] [Related]
13. Optimal therapy and prospects for new medicines in eosinophilic granulomatosis with polyangiitis (Churg-Strauss syndrome).
Pagnoux C; Groh M
Expert Rev Clin Immunol; 2016 Oct; 12(10):1059-67. PubMed ID: 27191665
[TBL] [Abstract][Full Text] [Related]
14. Targeting the interleukin-5 pathway in EGPA: evidence, uncertainties and opportunities.
Berti A; Atzeni F; Dagna L; Del Giacco S; Emmi G; Salvarani C; Vaglio A
Ann Rheum Dis; 2023 Feb; 82(2):164-168. PubMed ID: 36357156
[TBL] [Abstract][Full Text] [Related]
15. New-onset of eosinophilic granulomatosis with polyangiitis without eosinophilia and eosinophilic infiltration under benralizumab treatment: A case report.
Yonezawa H; Ohmura SI; Ohkubo Y; Otsuki Y; Miyamoto T
Mod Rheumatol Case Rep; 2023 Dec; 8(1):145-149. PubMed ID: 37243733
[TBL] [Abstract][Full Text] [Related]
16. [Eosinophilia: hypereosinophilic syndrome vs. eosinophilic granulomatosis with polyangiitis].
Holle JU; Moosig F
Z Rheumatol; 2023 May; 82(4):307-320. PubMed ID: 37099180
[TBL] [Abstract][Full Text] [Related]
17. Unmet needs and evidence gaps in hypereosinophilic syndrome and eosinophilic granulomatosis with polyangiitis.
Wechsler ME; Hellmich B; Cid MC; Jayne D; Tian X; Baylis L; Roufosse F
J Allergy Clin Immunol; 2023 Jun; 151(6):1415-1428. PubMed ID: 37086239
[TBL] [Abstract][Full Text] [Related]
18. Severe Asthma and Biologics: Managing Complex Patients.
Matucci A; Micheletto C; Vultaggio A
J Investig Allergol Clin Immunol; 2023 Jun; 33(3):168-178. PubMed ID: 36059229
[TBL] [Abstract][Full Text] [Related]
19. Nasal polyps in eosinophilic granulomatosis with polyangiitis: Structured histopathology and CD105 expression.
Brescia G; Padoan R; Schiavon F; Contro G; Parrino D; Tealdo G; Felicetti M; Frigo AC; Alessandrini L; Marioni G
Am J Otolaryngol; 2020; 41(6):102661. PubMed ID: 32810787
[TBL] [Abstract][Full Text] [Related]
20. Torasemide-induced Vascular Purpura in the Course of Eosinophilic Granulomatosis with Polyangiitis.
Frątczak A; Polak K; Miziołek B; Bergler-Czop B
Acta Dermatovenerol Croat; 2022 Sep; 30(2):116-118. PubMed ID: 36254546
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
